地诺单抗多少钱一支呢？

Also called denosumab, trade name: Xgeva. On May 27, 2019, Amgen China announced today that denosumab has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight ≥45 kg).

Denosumab was first approved in Europe for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

Denosumab is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Denosumab has a high affinity for RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women. 

For most patients, in addition to the therapeutic effect of the drug, what everyone wants to know most is the price of the drug. So, how much does denosumab cost?

Although it has been approved for marketing in my country, due to the short time to market and the conditional marketing, the price is not particularly clear at present. It is understood that the specification of denosumab marketed in the United States is 60mg/1ml tube/box, and the price is US$1,169.98. The price is relatively expensive, and many patients cannot afford it at all. However, the price of denosumab produced by the American company Amgen and marketed in Turkey is relatively low. The specification is 125mg/1ml tube/box. The price is equivalent to RMB 3,000, and patients can choose to buy it.